UKI-1 is a potent urokinase-type plasminogen activator (uPA) inhibitor (Ki = 0.41 μM) and a low molecular weight serine protease inhibitor; it acts as an effective anti-metastatic agent by inhibiting cancer cell invasion; it reduces tumor cell invasion by up to 50% in SCCHN FaDu and cervical carcinoma HeLa cell lines; it interferes with the plasminogen activation system by directly inhibiting plasmin formation and uPA activity; it effectively inhibits migration of highly invasive fibrosarcoma and breast cancer cells through fibrin matrices; it demonstrates significant anti-metastatic activity in vivo, reducing both metastatic lesion formation and tumor growth in rat models of metastasizing pancreatic and mammary adenocarcinoma.